

Paola Cinque

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8353348/publications.pdf>

Version: 2024-02-01

158
papers

9,565
citations

28274

55
h-index

40979

93
g-index

164
all docs

164
docs citations

164
times ranked

7990
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. <i>Journal of Experimental Medicine</i> , 2007, 204, 2899-2912.	8.5	630
2	Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. <i>Lancet, The</i> , 1993, 342, 398-401.	13.7	330
3	Changing incidence of central nervous system diseases in the EuroSIDA cohort. <i>Annals of Neurology</i> , 2004, 55, 320-328.	5.3	273
4	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. <i>Clinical Microbiology and Infection</i> , 2021, 27, 451-457.	6.0	243
5	Diagnosis of central nervous system complications in HIV-infected patients. <i>Aids</i> , 1997, 11, 1-17.	2.2	239
6	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. <i>Aids</i> , 1998, 12, 1327-1332.	2.2	226
7	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. <i>Aids</i> , 2012, 26, 1765-1774.	2.2	212
8	HIV-1 infection and cognitive impairment in the cART era: a review. <i>Aids</i> , 2011, 25, 561-575.	2.2	203
9	Progressive multifocal leukoencephalopathy and other forms of JC virus disease. <i>Nature Reviews Neurology</i> , 2010, 6, 667-679.	10.1	191
10	Progressive multifocal leukoencephalopathy in HIV-1 infection. <i>Lancet Infectious Diseases, The</i> , 2009, 9, 625-636.	9.1	187
11	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2010, 7, 15.	1.7	186
12	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. <i>Aids</i> , 1996, 10, 951-958.	2.2	184
13	Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. <i>Clinical Infectious Diseases</i> , 2013, 56, 1004-1017.	5.8	178
14	CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. <i>Blood</i> , 2013, 121, 4740-4748.	1.4	175
15	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	157
16	Analysis of the Systemic and Intrathecal Humoral Immune Response in Progressive Multifocal Leukoencephalopathy. <i>Journal of Infectious Diseases</i> , 1997, 176, 250-295.	4.0	154
17	Prognostic Significance of JC Virus DNA Levels in Cerebrospinal Fluid of Patients with HIV-Associated Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 2005, 40, 738-744.	5.8	142
18	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, 1703-1712.	4.0	142

#	ARTICLE	IF	CITATIONS
19	Cytomegalovirus Infection of the Central Nervous System in Patients with AIDS: Diagnosis by DNA Amplification from Cerebrospinal Fluid. <i>Journal of Infectious Diseases</i> , 1992, 166, 1408-1411.	4.0	141
20	Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. <i>Aids</i> , 2008, 22, 1759-1767.	2.2	141
21	A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. <i>Journal of NeuroVirology</i> , 2013, 19, 351-358.	2.1	138
22	Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity. <i>Journal of Infectious Diseases</i> , 2011, 204, 103-114.	4.0	135
23	Prevalence, Associated Factors, and Prognostic Determinants of AIDS-Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 1681-1691.	5.8	131
24	Highly Active Antiretroviral Therapy and Progressive Multifocal Leukoencephalopathy: Effects on Cerebrospinal Fluid Markers of JC Virus Replication and Immune Response. <i>Clinical Infectious Diseases</i> , 2000, 30, 95-99.	5.8	126
25	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. <i>BMC Neurology</i> , 2009, 9, 63.	1.8	126
26	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. <i>Journal of Infectious Diseases</i> , 2011, 204, 753-760.	4.0	125
27	The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology. <i>Journal of NeuroVirology</i> , 2003, 9, 88-92.	2.1	124
28	Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 565-571.	5.8	118
29	The Effect of Highly Active Antiretroviral Therapy-Induced Immune Reconstitution on Development and Outcome of Progressive Multifocal Leukoencephalopathy: Study of 43 Cases with Review of the Literature. <i>Journal of NeuroVirology</i> , 2003, 9, 73-80.	2.1	117
30	Cerebrospinal fluid HIV-1 RNA levels. <i>Aids</i> , 1998, 12, 389-394.	2.2	116
31	Real-Time PCR Assay for Clinical Management of Human Immunodeficiency Virus-Infected Patients with Visceral Leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5080-5084.	3.9	115
32	The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2001, 7, 358-363.	2.1	112
33	CSF neurofilament protein (NFL) is a marker of active HIV-related neurodegeneration. <i>Journal of Neurology</i> , 2007, 254, 1026-1032.	3.6	110
34	Elevated Cerebrospinal Fluid Neurofilament Light Protein Concentrations Predict the Development of AIDS Dementia Complex. <i>Journal of Infectious Diseases</i> , 2007, 195, 1774-1778.	4.0	103
35	JCV-DNA and BKV-DNA in the CNS Tissue and CSF of AIDS Patients and Normal Subjects. Study of 41 Cases and Review of the Literature. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 12, 139-146.	0.3	101
36	Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients. <i>Journal of Infectious Diseases</i> , 2011, 204, 237-244.	4.0	100

#	ARTICLE	IF	CITATIONS
37	Guidelines for the diagnosis and management of neurological complications of HIV infection. <i>European Journal of Neurology</i> , 2004, 11, 297-304.	3.3	97
38	Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy. <i>Current HIV/AIDS Reports</i> , 2015, 12, 280-288.	3.1	93
39	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. <i>Journal of Neurology</i> , 2013, 260, 620-626.	3.6	87
40	Cerebrospinal fluid interferon- β -inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. <i>Journal of Neuroimmunology</i> , 2005, 168, 154-163.	2.3	81
41	Varicella-Zoster Virus (VZV) DNA in Cerebrospinal Fluid of Patients Infected with Human Immunodeficiency Virus: VZV Disease of the Central Nervous System or Subclinical Reactivation of VZV Infection?. <i>Clinical Infectious Diseases</i> , 1997, 25, 634-639.	5.8	79
42	Smell and taste disorders in COVID-19: From pathogenesis to clinical features and outcomes. <i>Neuroscience Letters</i> , 2021, 748, 135694.	2.1	78
43	Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.	2.2	77
44	Herpes Simplex Virus Infections of the Central Nervous System in Human Immunodeficiency Virus-Infected Patients: Clinical Management by Polymerase Chain Reaction Assay of Cerebrospinal Fluid. <i>Clinical Infectious Diseases</i> , 1998, 27, 303-309.	5.8	74
45	Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls. <i>Clinical Infectious Diseases</i> , 2021, 73, e2838-e2839.	5.8	72
46	Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. <i>Journal of NeuroVirology</i> , 2002, 8, 432-438.	2.1	70
47	Specific diagnostic methods for herpesvirus infections of the central nervous system: A consensus review by the European Union Concerted Action on Virus Meningitis and Encephalitis. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 83-104.	1.7	67
48	Treating Progressive Multifocal Leukoencephalopathy With Interleukin 7 and Vaccination With JC Virus Capsid Protein VP1. <i>Clinical Infectious Diseases</i> , 2014, 59, 1588-1592.	5.8	64
49	JC polyomavirus mutants escape antibody-mediated neutralization. <i>Science Translational Medicine</i> , 2015, 7, 306ra151.	12.4	64
50	MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. <i>Journal of Leukocyte Biology</i> , 1997, 62, 30-33.	3.3	60
51	Diagnosis and Clinical Management of Neurological Disorders Caused by Cytomegalovirus in Aids Patients. <i>Journal of NeuroVirology</i> , 1998, 4, 120-132.	2.1	60
52	Molecular analysis of cerebrospinal fluid in viral diseases of the central nervous system. <i>Journal of Clinical Virology</i> , 2003, 26, 1-28.	3.1	60
53	Cytomegalovirus Infections of the Nervous System. <i>Intervirology</i> , 1997, 40, 85-97.	2.8	59
54	Analysis of the transcriptional control region in progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2000, 6, 398-409.	2.1	59

#	ARTICLE	IF	CITATIONS
55	Progressive Multifocal Leukoencephalopathy, HIV, and Highly Active Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1998, 339, 848-849.	27.0	58
56	Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma. <i>Clinical Infectious Diseases</i> , 2006, 42, e21-e25.	5.8	58
57	An international external quality assessment of nucleic acid amplification of herpes simplex virus. <i>Journal of Clinical Virology</i> , 2003, 28, 175-185.	3.1	49
58	Ganciclovir Therapy for Cytomegalovirus (CMV) Infection of the Central Nervous System in AIDS Patients: Monitoring by CMV DNA Detection in Cerebrospinal Fluid. <i>Journal of Infectious Diseases</i> , 1995, 171, 1603-1606.	4.0	47
59	Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. <i>Journal of Virological Methods</i> , 1997, 69, 231-237.	2.1	46
60	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	3.0	46
61	Use of Polymerase Chain Reaction Assays of Aqueous Humor in the Differential Diagnosis of Retinitis in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1997, 24, 1100-1106.	5.8	45
62	Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 112-119.	4.1	45
63	The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated <i>Toxoplasma gondii</i> encephalitis in patients with AIDS. <i>Journal of Medical Microbiology</i> , 2002, 51, 879-890.	1.8	45
64	Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2005, 10, 701-707.	1.0	44
65	Nested PCR for detection of BK virus and JC virus DNA. <i>Clinical and Diagnostic Virology</i> , 1994, 2, 211-220.	1.7	42
66	Remission of AIDS-associated progressive multifocal leukoencephalopathy after zidovudine therapy. <i>Journal of Neurology</i> , 1999, 246, 723-725.	3.6	41
67	Elevated levels of soluble Fas and Fas ligand in cerebrospinal fluid of patients with AIDS dementia complex. <i>Journal of Neuroimmunology</i> , 2001, 114, 197-206.	2.3	41
68	Effect of Genotypic Resistance on the Virological Response to Highly Active Antiretroviral Therapy in Cerebrospinal Fluid. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 377-383.	1.1	41
69	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 347-359.	3.0	41
70	The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. <i>Annals of Neurology</i> , 2004, 55, 687-694.	5.3	40
71	Defining cerebrospinal fluid HIV RNA escape. <i>Aids</i> , 2019, 33, S107-S111.	2.2	40
72	Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 386-392.	1.1	37

#	ARTICLE	IF	CITATIONS
73	Brainstem encephalitis resulting from Epstein-Barr virus mimicking an infiltrating tumor in a child. <i>Pediatric Neurology</i> , 2000, 22, 130-132.	2.1	33
74	Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. <i>Journal of Neuroimmunology</i> , 2004, 157, 133-139.	2.3	32
75	Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. <i>Scientific Reports</i> , 2015, 5, 13647.	3.3	32
76	Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. <i>Neurological Sciences</i> , 2001, 22, 17-20.	1.9	30
77	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. <i>BMC Infectious Diseases</i> , 2017, 17, 61.	2.9	30
78	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019, 85, 606-610.	5.3	30
79	Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. <i>Aids</i> , 1993, 7, 209-212.	2.2	29
80	Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. <i>Mitochondrion</i> , 2011, 11, 520-527.	3.4	29
81	Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , 2012, 130, 2990-2996.	5.1	29
82	Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. <i>Antiviral Therapy</i> , 2005, 10, 701-7.	1.0	29
83	Age-dependent neurologic manifestations of HIV infection in childhood. <i>Neurological Sciences</i> , 2000, 21, 135-142.	1.9	28
84	Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2039-2046.	3.0	28
85	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105893.	2.5	28
86	Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2005, 19, S151-S165.	2.2	27
87	Comparison of Three Nucleic Acid Amplification Assays of Cerebrospinal Fluid for Diagnosis of Cytomegalovirus Encephalitis. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1148-1151.	3.9	26
88	Progressive Multifocal Leukoencephalopathy in a Child with Hyperimmunoglobulin E Recurrent Infection Syndrome and Review of the Literature. <i>Neuropediatrics</i> , 2001, 32, 250-255.	0.6	26
89	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021, 27, 331-346.	3.0	26
90	A Mobile Application for Exercise Intervention in People Living with HIV. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 425-433.	0.4	25

#	ARTICLE	IF	CITATIONS
91	The Role of Physical Activity for the Management of Sarcopenia in People Living with HIV. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1283.	2.6	25
92	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012, 35, 113-59.	0.1	25
93	Investigation on the role of cell transcriptional factor Sp1 and HIV-1 TAT protein in PML onset or development. <i>Journal of Cellular Physiology</i> , 2005, 204, 913-918.	4.1	24
94	Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 85, 261-300.	1.8	24
95	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 243-250.	0.5	22
96	Coinfection of the central nervous system by cytomegalovirus and herpes simplex virus type 1 or 2 in AIDS patients: autopsy study on 82 cases by immunohistochemistry and polymerase chain reaction. <i>Acta Neuropathologica</i> , 1996, 92, 404-408.	7.7	21
97	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	2.1	21
98	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	2.2	19
99	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
100	Long-Term Remission of HIV-Associated Primary CNS Lymphoma Achieved With Highly Active Antiretroviral Therapy Alone. <i>Journal of Clinical Oncology</i> , 2012, 30, e119-e121.	1.6	18
101	Broad screening for human herpesviridae DNA in multiple sclerosis cerebrospinal fluid and serum. <i>Acta Neurologica Belgica</i> , 2009, 109, 277-82.	1.1	18
102	Symptomatic cerebrospinal fluid escape. <i>Aids</i> , 2019, 33, S159-S169.	2.2	17
103	Analysis of JC Virus Genotype Distribution and Transcriptional Control Region Rearrangements in Human Immunodeficiency Virus-Positive Progressive Multifocal Leukoencephalopathy Patients with and without Highly Active Antiretroviral Treatment. <i>Journal of NeuroVirology</i> , 2003, 9, 42-46.	2.1	16
104	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	3.0	16
105	Spatial Working Memory in Asymptomatic HIV-Infected Subjects. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 387-391.	1.8	15
106	The Effect of Highly Active Antiretroviral Therapy-Induced Immune Reconstitution on Development and Outcome of Progressive Multifocal Leukoencephalopathy: Study of 43 Cases with Review of the Literature. <i>Journal of NeuroVirology</i> , 2003, 9, 73-80.	2.1	15
107	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	5.8	15
108	Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. <i>Aids</i> , 2001, 15, 1109-1113.	2.2	14

#	ARTICLE	IF	CITATIONS
109	Progressive multifocal leukoencephalopathy in an adult patient with ICF syndrome. <i>Journal of the Neurological Sciences</i> , 2004, 217, 107-110.	0.6	14
110	Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: Modes of response and correlation with markers of HIV replication. <i>European Journal of Haematology</i> , 1993, 50, 17-21.	2.2	14
111	Detection of DNA of Lymphotropic Herpesviruses in Plasma of Human Immunodeficiency Virus-Infected Patients: Frequency and Clinical Significance. <i>Vaccine Journal</i> , 2002, 9, 1222-1228.	3.1	13
112	Central Nervous System HIV Infection in Less-Drug Regimen Antiretroviral Therapy Simplification Strategies. <i>Seminars in Neurology</i> , 2014, 34, 078-088.	1.4	13
113	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.	2.2	13
114	Disseminated rhodococcus equi infection in HIV infection despite highly active antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2011, 11, 343.	2.9	12
115	Active intrathecal herpes simplex virus type 1 (HSV-1) and human herpesvirus-6 (HHV-6) infection at onset of multiple sclerosis. <i>Journal of NeuroVirology</i> , 2012, 18, 437-440.	2.1	12
116	No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau). <i>Virulence</i> , 2017, 8, 599-604.	4.4	12
117	Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 2018, 67, 65-72.	5.8	12
118	Clinical Epidemiology and Survival of Progressive Multifocal Leukoencephalopathy in the Era of Highly Active Antiretroviral Therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). <i>Journal of NeuroVirology</i> , 2003, 9, 47-53.	2.1	12
119	Pharmacokinetics of Zidovudine in HIV-Positive Patients with Liver Disease. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 782-786.	2.0	11
120	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2015, 18, 20037.	3.0	11
121	The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus Terminology. <i>Journal of NeuroVirology</i> , 2003, 9, 88-92.	2.1	11
122	Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin-7. <i>Annals of Neurology</i> , 2022, 91, 496-505.	5.3	11
123	Positive Predictive Value of Epstein-Barr Virus DNA Detection in HIV-Related Primary Central Nervous System Lymphoma. <i>Clinical Infectious Diseases</i> , 2004, 39, 1396-1397.	5.8	10
124	Distal Sensory Peripheral Neuropathy in Human Immunodeficiency Virus Type 1-Positive Individuals Before and After Antiretroviral Therapy Initiation in Diverse Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2020, 71, 158-165.	5.8	10
125	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. <i>Lancet</i> , 1991, 337, 1488.	13.7	9
126	Molecular Studies of Cerebrospinal Fluid in Human Immunodeficiency Virus Type 1-Associated Opportunistic Central Nervous System Diseases—An Update. <i>Journal of NeuroVirology</i> , 2002, 8, 122-128.	2.1	9

#	ARTICLE	IF	CITATIONS
127	Epstein-Barr virus DNA in the cerebrospinal fluid of an HIV patient with primary cerebral lymphoma. <i>European Journal of Pediatrics</i> , 1998, 157, 291-293.	2.7	8
128	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1637-1642.	3.0	8
129	Relapse of Symptomatic Cerebrospinal Fluid HIV Escape. <i>Current HIV/AIDS Reports</i> , 2020, 17, 522-528.	3.1	8
130	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.	2.2	8
131	Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases. <i>Journal of NeuroVirology</i> , 2009, 15, 99-107.	2.1	7
132	Nested PCR for detection of BK virus and JC virus DNA. <i>Clinical and Diagnostic Virology</i> , 1994, 2, 127-136.	1.7	6
133	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United Tj ETQq1 1 0.784314 r gBT /Overl</i>	1.7	6
134	Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2. <i>Aids</i> , 2007, 21, 1223-1225.	2.2	5
135	Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-7.	0.7	5
136	Neurological complications of HIV infection and AIDS: Current and future perspectives. <i>Journal of NeuroVirology</i> , 2005, 11, 1-5.	2.1	5
137	Serum Polymerase Chain Reaction for Cytomegalovirus DNA for Monitoring Ganciclovir Treatment in AIDS Patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1996, 28, 347-351.	1.5	4
138	Letter to the Editor. <i>Multiple Sclerosis Journal</i> , 2006, 12, 674-675.	3.0	4
139	Susacâ€™s syndrome as HIV-associated immune reconstitution inflammatory syndrome. <i>AIDS Research and Therapy</i> , 2013, 10, 22.	1.7	4
140	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	2.5	4
141	Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid. <i>Annals of the New York Academy of Sciences</i> , 1994, 724, 170-172.	3.8	3
142	Management Strategies for Herpesvirus Infections of the CNS. <i>CNS Drugs</i> , 2000, 14, 95-113.	5.9	3
143	Acquisition of human immunodeficiency virus infection in a patient with multiple sclerosis: could these conditions positively influence each otherâ€™s course?. <i>Journal of NeuroVirology</i> , 2020, 26, 957-960.	2.1	3
144	Diagnosis of Polyomavirus Infection, Replication, and Disease. <i>Infectious Disease and Therapy</i> , 2010, , 401-424.	0.0	2

#	ARTICLE	IF	CITATIONS
145	Diagnostic and prognostic significance of β 2-microglobulin during HIV infection. <i>Research in Clinic and Laboratory</i> , 1990, 20, 105-111.	0.3	2
146	Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 715-8.	1.4	2
147	The Application of the Polymerase Chain Reaction of Cerebrospinal Fluid in the Clinical Management of AIDS-Related CNS Disorders. <i>AIDS Patient Care and STDs</i> , 1998, 12, 287-294.	2.5	1
148	Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. <i>Viral Immunology</i> , 2017, 30, 622-626.	1.3	1
149	Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1646-1648.	3.0	1
150	Benefits of a 12-week physical activity programme on muscle and bone health in people living with HIV. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, , .	7.3	1
151	CSF Analysis in the Diagnosis of Viral Encephalitis and Meningitis. , 2003, , .		1
152	Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients. <i>New Microbiologica</i> , 2008, 31, 435-8.	0.1	1
153	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	2.1	0
154	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004, 10, 52-57.	2.1	0
155	HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2994-2997.	3.0	0
156	Cerebrospinal Fluid Markers in the Management of Central Nervous System HIV Infection and the AIDS Dementia Complex. , 0, , 173-179.		0
157	Progressive Multifocal Leukoencephalopathy and HIV. , 2016, , 1-13.		0
158	Progressive Multifocal Leukoencephalopathy and HIV. , 2018, , 1755-1767.		0